Value Based Care Intelligence

RadiantGraph sits on the payer side of the engagement problem, which distinguishes it from every other record in this part of the index. Clearstep, Keona Health and Loyal Health all sell to providers and wait for a patient to arrive. This platform sells to health plans and health services organisations and goes outward, deciding which members to contact, about what, through which channel, and then placing the call itself. The architecture is two layers and both are model driven. The personalisation layer ingests member data from the customer's own infrastructure, with integrations to Amazon Web Services, Google Cloud, Snowflake and Databricks, and builds per person models that determine who to engage and how. The company stated it was processing personalisation models for more than 3.5 million people at its Series A. On top of that sits AI Voice Studio, launched in June 2025, which runs automated omnichannel outbound calling campaigns using conversational agents rather than recorded messages or live agents. Named use cases span pharmacy operations, Medicare and individual plan onboarding, preventative care outreach, benefit utilisation, chronic disease management, member education, adherence support and care navigation, with client programmes covering substance use, mental health, chronic conditions and musculoskeletal care. The evidence is the strongest thing on this record and it is unusual for a company this size. A study conducted with Oshi Health, a virtual first gastrointestinal specialty clinic, ran over seven weeks with nearly 8,800 members across three journey stages in the fourth quarter of 2025, and was published in a peer reviewed paper presented at the 2026 International Conference on Artificial Intelligence in Medicine in Ottawa, appearing in Lecture Notes in Artificial Intelligence with a citable identifier. Reported results include appointment completion up 3.4 times overall and 24.7 times among members who had created an account without scheduling, a 9 times increase in outbound call volume against human agents, roughly 75 hours of staff time saved per 1,000 contacts, and no safety incidents or escalations identified. Very few vendors in this index take a deployment to a peer reviewed venue at all. The security posture is equally unusual. The company states HITRUST certification alongside service organisation control type 2 and health privacy statute compliance. HITRUST is the most demanding of the three, it incorporates the others, and it is expensive enough that a company of roughly 21 employees holding it is a deliberate choice rather than a box ticked. Founded and launched in September 2023 in San Francisco by Anmol Madan, an MIT doctorate holder who previously co founded and led Ginger and served as chief data scientist at Livongo and Teladoc. Roughly $19.1M raised across a $5M seed and an $11M Series A led by M13 with True Ventures and XYZ Ventures, and an angel list drawn from the executive ranks of Transcarent, Livongo, LiveRamp and Harris Health. One thing a reader should weigh. The published study is a collaboration between the vendor and its own customer rather than independent work, and its headline figures are multiples without stated absolute baselines, so the effect direction is well evidenced and its magnitude is not independently checkable.

Cedar Gate Technologies is the vendor in this lane that actually moves the money. Most value based care platforms measure performance under a risk contract and hand the result to someone else to act on. Cedar Gate does that and then adjudicates the payment, running bundled and capitated arrangements end to end on software rather than on spreadsheets and manual reconciliation. The platform has four layers on one data foundation. Enterprise data management ingests claims, clinical, eligibility and benefits data into a single lake, cleanses and normalises it and stitches records to members. Analytics sits above it, covering value based care performance, benefits analytics for self funded employers and benchmarking against an anonymised database described as covering 12 million member lives. Care management supplies workflow and engagement. Payment technology adjudicates, with a bundles engine acquired in 2018 that automatically converts fee for service claims into a single bundled claim and manages the payment between payer and provider, and a separate capitation engine that administers capitated agreements and eligibility. Most of that estate was bought rather than built. The company was founded in 2014 by David Snow, previously chief executive of a large pharmacy benefit manager, with backing from a private equity firm, and launched its own analytics tool in 2016. Global Healthcare Alliance followed in 2018, bringing the bundled payment engine and a lineage in bundled payments the company now describes as spanning more than forty years, then Citra Health Solutions, Deerwalk and Enli Health Intelligence in 2020. Ownership changed in late 2025, when IQVIA acquired the company in a transaction reported at around 750 million dollars. The brand continues to be sold under its own name as an IQVIA business and product launches have continued since, including a prospective bundled payment suite in March 2026 supporting the mandated Transforming Episode Accountability Model, so the change of owner does not alter how this record reads. Buyers span health plans, provider organisations, self funded employers, third party administrators and advisers, across commercial, Medicare and Medicaid lines and across primary care attribution, shared savings, bundles and capitation. Named customers include Kairos Health Arizona, MedBen and Baptist Memorial Health Care. Roughly 1,000 employees across offices in Greenwich, Burlington and Houston, a large remote workforce and a team in Nepal. Two things a reader should weigh. A bundled payment case study presented at an industry summit in 2026 reports 97 percent patient satisfaction, 91 percent avoided inpatient hospital care, a 60 percent reduction in total cost of care and a 50 percent reduction in surgical rates, and figures of that magnitude carry no denominator, period, comparison group or stated method. And a dedicated pass located no security certification of any kind and no pricing of any kind.

Inovalon is a data business that sells analytics, and the data asset is the reason it matters. The MORE2 Registry, its Medical Outcomes Research for Effectiveness and Economics dataset, is described as drawing on more than 160 primary sources across all fifty states and holding upwards of 99 billion medical, pharmacy and laboratory events covering 1.1 million clinicians and hundreds of millions of unique lives. The company is also a Qualified Entity under the Centers for Medicare and Medicaid Services programme of that name, which permits access to complete Medicare fee for service data for defined purposes. Very few organisations hold a comparable position, and everything else the company sells rests on it. Inovalon ONE is the platform layer, combining national scale connectivity to electronic health record systems and health information exchanges with real time primary source data and analytics, and it carries more than 100 software solutions reached through a single sign on portal. Four buyer markets are served from it. Payer products centre on Converged Quality, which supports quality measurement, reporting and improvement across HEDIS, Medicare star ratings and state programmes. Provider products, built on the acquired ABILITY Network and now the Provider Cloud, cover revenue cycle, care quality and workforce management. Pharmacy products serve specialty and infusion operations. Life sciences products license data and analytics for research, health economics and trial work. This record grades the company as one entity because a single platform, a single data asset and a single compliance posture underlie all four lines. Two ownership points sit alongside it. VigiLanz, acquired in February 2024 and graded separately in this index, is still sold under its own name and its record documents the ownership. And Inovalon was taken private in August 2021 at an enterprise value of roughly 7.3 billion dollars by a consortium led by Nordic Capital with Insight Partners, 22C Capital and founder and chief executive Keith Dunleavy. The external validation record is the strongest in this lane. Converged Quality earned its twenty sixth consecutive National Committee for Quality Assurance measure certification in July 2026 together with validation of its digital quality measure engine, and took the 2026 category award for quality measurement and reporting analytics in a research firm's customer survey. The company states more than 100 health plans use the product, representing a majority of enrolment in four star and above Medicare Advantage plans, alongside more than 50,000 licensed customers overall. Headquartered in Bowie, Maryland. Two things a reader should weigh. Data gathered while serving payers and providers also supports a licensing business selling data and analytics to pharmaceutical and life sciences customers, and no published statement explains what permissions govern that second use. And no pricing of any kind was located.

Lightbeam Health Solutions assembles a value based care operating system largely by acquisition, and the pieces it bought explain what it is. The core platform aggregates data from many sources, normalises and represents it, mines it for care gaps, performs risk stratification and returns the result to providers at the point of care. Around that core sit three purchased businesses. CareSignal, acquired in November 2021, contributes what the company brands Deviceless Remote Patient Monitoring, a text message and telephone based monitoring approach with condition specific programmes. Jvion, whose operating assets were acquired in 2022, contributes prescriptive analytics that combine clinical, socioeconomic, environmental and behavioural data to identify patients on a trajectory toward becoming high risk and to indicate which interventions would change that trajectory, together with social determinants and health equity capability. Syntax Health, acquired in December 2025, contributes contract modelling, incentive design and actuarial services, which extends the company from measuring performance under a risk contract to helping design the contract itself. The evidence base is stronger than most records in this lane and it comes from outside the company. The remote monitoring product was ranked first in its category in a research firm's 2024 customer survey, a ranking derived from client responses rather than vendor submissions. Recognition as a Microsoft healthcare and life sciences partner of the year followed in 2025, and the care orchestration suite is transactable through that vendor's cloud marketplace. The company states that in the 2022 performance year its accountable care organisation clients managed care for 1.1 million patients. Harris County Public Health is a named public sector customer of the monitoring product. Security certification is at the top tier of the healthcare assurance framework and carries a visible history, with initial certification in January 2022 and renewal at the risk based two year level in February 2024. A quality reporting capability supporting accountable care organisations migrating to fully electronic measure reporting is a concrete piece of interoperability work rather than a claim. Founded and led by Pat Cline, previously a long serving executive at an electronic health record company, and backed by Hearst and Primus Capital. Headquartered in the Dallas area. Two things a reader should weigh. The branded monitoring category is described as deviceless, and federal remote physiologic monitoring reimbursement generally requires data transmitted automatically from a medical device, so a buyer should establish directly whether a given programme is billable under those codes or is a clinically useful engagement programme funded another way. And no pricing of any kind was located.

Persivia sells accountable care organisations and health plans a single platform for running risk contracts, and the platform carries a longer history than its current positioning suggests. CareSpace aggregates clinical records, claims, health information exchange feeds, admission and discharge messages, patient reported data, home device readings and social determinants information into a longitudinal patient record, then layers risk stratification, care management, quality reporting, care gap identification and patient outreach on top of it. The company describes the product as built on more than a decade of clinical rules engine and analytics work combined with clinical content expertise, which is an unusually candid account of its own lineage and matters for how the intelligence claims should be read. The content library is the distinguishing asset. More than 200 evidence based programmes cover chronic disease management, care transitions, preventive care, behavioural health and social determinants, each combining a care pathway with analytics, and customers deploy them as shipped or adapt them to local practice and payer requirements. Buying a configured programme rather than building a protocol is the difference between going live in weeks and going live in quarters, and the company claims a data pipeline operational in eight weeks against a stated industry norm of six to twelve months. Patient contact is automated and the company is direct about why. Software agents conduct natural language text message and voice outreach for follow ups, appointment reminders, medication adherence and chronic care education, described explicitly as keeping patients engaged without requiring additional staff capacity. Social determinant flags drive targeted outreach to groups least likely to meet outcome thresholds. External credentials are held rather than asserted. The company earned the Certified Data Partner designation in the National Committee for Quality Assurance Data Aggregator Validation programme in January 2025, the same credential Arcadia holds, and CareSpace secured HITRUST implemented one year certification in March 2024. Earlier recognition includes a best decision support system award for accountable care organisations from an industry survey firm. Founded and led by clinician entrepreneurs, headquartered in Marlborough, Massachusetts, and recapitalised in April 2025 in a 107 million dollar transaction with Aldrich Capital Partners, which holds the company alongside Petrichor Healthcare Capital Management. Two things a reader should weigh. The most specific outcome figures attached to this platform, including a shared savings result, a national ranking among Medicare Shared Savings Program participants and a large readmission reduction, appear in a comparison of the top eight platforms in this market published by Persivia itself, which is a vendor ranking a field that includes the vendor. And no pricing of any kind was located.

Health Catalyst sells health systems the data layer beneath their improvement work, plus the people to run it. The company describes two operating segments in its filings. Technology is the larger and covers a cloud data platform, analytics applications and support, sold as cloud subscriptions and term licences. Professional Services covers analytics, implementation, strategic advisory, outsourcing and improvement services, positioned as the expertise a customer needs to configure and actually use the technology. That structure is the defining fact about this company: the improvement outcomes it markets are attributed to the combination of software and expert labour rather than to software alone. Ignite is the current platform. It ingests electronic health record, claims, financial and operational data through prebuilt source starter sets, profiles it for quality, resolves patient and provider identity, and exposes a unified data model that customers query with their own business intelligence and modelling tools if they prefer. Ignite Intelligence, introduced in 2025, layers shared models, software agents, benchmarks and comparison services on top. Clinical Cost Intelligence is the flagship example and its published method is unusually specific for this lane, combining supply normalisation, ontology mapping, machine learning driven variation analysis and large language model assisted opportunity screening to move service line costing from months of analysis to immediate results. Healthcare.AI is sold as a mix of self service model building products and expert services covering analytics integration, model selection and model optimisation. Much of the estate arrived by acquisition and is co branded rather than absorbed. Twistle, Upfront and Lumeon are all sold as products by Health Catalyst, a patient engagement tool, a patient experience platform and a care orchestration engine respectively. An interoperability and health information exchange suite carries the company name after having been acquired as Medicity. Registry, quality measure and revenue cycle applications sit alongside them. Security disclosure is the strongest part of the public record. A dedicated information security page enumerates which certifications cover which named products, with framework versions and explicit coverage periods, spanning HITRUST certification across three business unit product families and audited reports at the type two assurance level. Recertification has continued through 2025 across the acquired brands. More than 1,100 organisations are stated to use the offerings, across hundreds of millions of patient records. Headquartered in Salt Lake City and listed on the Nasdaq exchange. Three things a reader should weigh. Trailing twelve month revenue stood at roughly 302 million dollars as of March 2026 against a market capitalisation of roughly 154 million dollars at the end of July 2026, a company valued below one year of revenue, and a buyer signing a multi year data platform contract should form its own view of what that indicates. Revenue growth is described as modest with full year guidance reduced and restructuring under way. And the headline claim of billions of dollars in measurable results appears across company material with no method, no time period and no breakdown.

Arcadia sells the data foundation underneath value based care, and increasingly the models that run on top of it. The platform ingests clinical records from electronic health record systems, payer claims, admission and discharge feeds, pharmacy data and social determinants information, resolves them to a single member through a proprietary master patient index, applies natural language processing to unstructured text, and presents the curated result to population health, risk, quality and network teams. Named components include a data gateway that handles ingestion and monitors for quality anomalies, a lakehouse platform layer, Arcadia Vista for value based care insights, Network Modeler, Contract IQ, Provider Intelligence, and an AI Factory positioned as an analyst facing environment for building predictive models on a customer's own data. A point of care assistant is the company's first generative artificial intelligence product. Two ownership events shape what the company is now. CareJourney, acquired in June 2024, supplied national benchmark data derived from Medicare claims, which gave Arcadia an external comparison set rather than only the data its customers bring to it. In July 2025 Nordic Capital took ownership. The brand is still sold under its own name and the product line has expanded since, so the change of owner does not alter how this record reads. Credentials in the quality domain are held rather than asserted. The company earned the Certified Data Partner designation in the National Committee for Quality Assurance Data Aggregator Validation programme, and separately a Validated Data Stream designation covering the use of its clinical data for HEDIS performance measurement. That second one matters more than it sounds, because it means an external body examined whether data flowing through this platform is fit to be scored on rather than taking the vendor's word for it. Security credentials are long standing: ISO 27001 in 2017, a SOC 2 Type One report in 2019, HITRUST CSF certification in 2020, and top ratings across every category in an independent cybersecurity preparedness evaluation conducted by KLAS Research and Censinet, an exercise roughly ten percent of eligible vendors agreed to enter. Buyers are health systems, provider groups, accountable care organisations and health plans operating under shared savings, ACO REACH, Medicaid and commercial risk contracts. Named customers include Southwestern Health Resources, Tandigm, Castell, Rush Health and Beth Israel Lahey Health. Three things a reader should weigh. The published outcome figures, including 81 percent in visit diagnosis capture, 59 percent more closed risk per patient and a 24 percent reduction in inpatient admissions, carry no denominator, no time period and no stated method. The most recent security report located is a SOC 2 Type One rather than a Type Two, which tests whether controls are designed correctly rather than whether they operated correctly over a period. And a dedicated pass located no pricing of any kind.

Astrata reads clinical charts so quality teams do not have to. The company builds natural language processing for healthcare quality measurement, aimed squarely at the HEDIS reporting that determines health plan star ratings and quality bonus payments. Chart Review performs assisted abstraction for prospective, year round HEDIS work rather than the annual scramble. A separate text platform exposes the same unstructured data capability for risk adjustment and other chart based activities. eMeasure is a measure engine built natively on FHIR and CQL. Quality Navigator applies the same analysis to targeting member and patient outreach. The technology has an unusually documented lineage. The company describes a platform developed over almost two decades with National Institutes of Health funding, combining multiple natural language processing, machine learning and artificial intelligence techniques. It was spun out of UPMC Enterprises as an independent company, with the first product built alongside UPMC Health Plan to underpin that plan's own prospective HEDIS programme, so the initial customer was also the co developer. Credentials in this domain are held rather than claimed. eMeasure was among the first digital HEDIS engines to earn National Committee for Quality Assurance certification for new digital measures, initially covering breast and colorectal cancer screening, achieved with a FHIR data platform partner. The company states it is the only recipient of the accrediting body's data partner certification for natural language processing assisted clinical document enrichment, and one of only three companies invited into that body's natural language processing working group. Separately it holds HITRUST r2 certification, the highest assurance tier of the health specific security framework. The disclosure practice around accuracy deserves particular attention because it is rare. The company states that it measures natural language processing performance at every stage from measure development through tuning to performance in production, and that it supplies customers with the reports and tooling to see that accuracy directly and to satisfy their own auditors. It reports that customers have had a complete success rate with accrediting body auditors, which is the operational test that matters in this field, since a quality submission that cannot survive audit is worthless. Based in Pittsburgh and led by chief executive Rebecca Jacobson. Buyers are health plans and accountable care organisations. The company also publishes a page setting out what it is and is not, which is a deliberate scoping exercise few vendors attempt. No pricing of any kind was located, and no public accuracy figures are published, though customers receive them.

Clarify Health sells predictions built on one of the largest linked healthcare datasets in the United States. The Clarify Atlas Platform maps longitudinal patient journeys across more than 300 million unique lives, assembled from health plan claims, pharmacy data, government sources and negotiated pricing rates, and generates a stated 20 billion or more machine learning predictions on top of it. Applications sit above that foundation as modular building blocks, covering provider network design and optimisation, referral pathway analysis, cost containment, quality and utilisation assessment, population health, value based care performance and pharmaceutical commercialisation. The method has been described by the company's own leadership as applying the analytical approach popularised in professional sports to healthcare, objectively assessing hospital and clinician performance and connecting clinical results to financial incentives. A Performance IQ Suite launched in October 2024 spans cost, quality and utilisation together, using machine learning and natural language processing, and a separate product supports referral network optimisation and care pathway analytics. Buyers span the ecosystem rather than one segment: health systems, physician groups, ambulatory surgical centres, health plans, technology and services organisations, and life sciences companies. Independent recognition is substantial and consistent. A major analyst firm ranked the company first for data analytics platforms serving payers, and a large software marketplace named the platform the top vendor in its relationship index for healthcare analytics in its Winter 2025 report, alongside high performer and momentum leader designations, all derived from customer reviews. Based in San Francisco and led by chief executive Jean Drouin with founder and president Todd Gottula. Roughly 411 million dollars has been raised across ten rounds from 24 investors, including a 150 million dollar round in 2022 at a valuation of 1.4 billion dollars. Three things a reader should weigh. Headcount stood at 116 as of March 2026, which is small relative to the capital raised and the valuation recorded in 2022, and a buyer should form its own view of what that indicates. A headline claim of 2.6 billion dollars in customer verified return appears throughout company material with no method, no verification process and no per customer breakdown disclosed. And a dedicated pass located no named customer, no security attestation, no data handling statement and no account of where the 300 million life dataset comes from or on what legal basis it is assembled.

ClosedLoop builds predictive models for healthcare organisations and explains them. The platform supplies off the shelf models for common use cases, automates the data preparation that consumes most of a healthcare data scientist's time, and produces individual level risk predictions rather than population scores. Named applications include predicting admissions and readmissions, total utilisation and total risk, emergency department over utilisation, out of network utilisation, appointment non attendance, and the onset or progression of chronic disease. The distinguishing credential is competitive and adjudicated rather than self reported. In April 2021 the company won the grand prize in the Centers for Medicare and Medicaid Services Artificial Intelligence Health Outcomes Challenge, a multi stage competition begun in 2019 and run by the agency's innovation centre with the American Academy of Family Physicians and Arnold Ventures. It beat more than 300 entrants including IBM, Mayo Clinic, Merck, Accenture and Deloitte, with Geisinger the runner up. What the challenge asked for matters as much as who won it: the brief was explicitly for explainable artificial intelligence that front line clinicians could understand and trust, applied to predicting unplanned admissions and adverse events among Medicare beneficiaries. An independent federal body ran a two year contest on explainability and this company came first. That design shows in the product. Each Patient Health Forecast presents a prediction alongside the specific variables driving it and links to interventions a clinical team can act on, so a clinician receives a reason and a next step rather than a number. Independent recognition continued afterwards, with the top rating in a major analyst firm's healthcare artificial intelligence data science category in 2022, 2023 and 2024. Published work includes an open sourced vulnerability index released during the pandemic, documented in a medical artificial intelligence journal and stated to have reached more than 10 million lives, and a collaboration with a value based primary care provider published in a clinical management journal. Named customers span a large nonprofit health plan, the largest Medicaid accountable care organisation, a long term care accountable care organisation, physician groups and a federal contractor. Based in Austin, Texas, with roughly 48 million dollars raised including a 34 million dollar Series B in August 2021. Two cautions. One named customer also participated as an investor in that round, so any reference from it carries a commercial interest. And no company announcement, funding event or product release was located after February 2024, which is a gap a buyer should resolve directly before relying on current capability. No pricing, security attestation or data handling statement was found.

Behavioral health integration infrastructure sold to risk bearing organisations, health systems and health plans rather than to patients. Founded 2016 in Philadelphia by Chris Molaro, chief executive, and Adam Pardes, chief operating officer; one source gives 2017. Funding totals roughly 58 million dollars, including a 20 million dollar Series B led by Magellan Health and a 25 million dollar growth round led by SEMCAP Health, with a later private equity round. The premise is that behavioral health need surfaces in physical care settings that are not equipped to handle it. Three named products address that in sequence. BHIQ applies machine learning across claims, record system, admission discharge transfer and assessment data to surface undiagnosed and undertreated behavioral health conditions across a population. IntegrateBH, expanded in February 2026 with capabilities from recent acquisitions, operationalises those findings through risk identification, intelligent referral matching and care coordination, delivering patient data inside the provider's existing workflow. TxProgress measures treatment impact over time. One component distinguishes this record from every other behavioral health vendor in the index and should be read against them directly. NeuroFlow operates Response Services, a human staffed safety net for crisis moments, which the company describes as unique in its ability and willingness to address suicidality. The two patient facing conversational products built immediately before this one, Wysa and Limbic, publish no crisis escalation pathway at all. This company sells one. Named customers include Magellan Health, Trinity Health, Bozeman Health and the Department of Defense, with platform reach reported at roughly 15 million patients. Note that Magellan Health is both a customer and the investor that led the Series B, so that reference is not disinterested. The company was a finalist in a federal grand challenge to reduce veteran suicide, receiving 250,000 dollars and advancing to a second phase, which is competitive government evaluation rather than a marketing award. Security credentials are stated correctly and with their tiers: health specific certification at the implemented one year level, a controls report at the second type, and privacy compliance. A published example reports a large integrated health system stratifying more than 3,000 patients within four months. The gaps are measurement and commerce. No accuracy figure is published for the risk identification models, no peer reviewed evidence was located, and nothing about pricing is disclosed.

Autonomous medical coding and clinical quality abstraction on one engineering stack. The coding product assigns ICD-10, CPT and HCPCS codes across specialties with a source cited justification for every code, scrubs for compliance and can submit directly to the billing system. The quality product abstracts, calculates and submits measures to CMS, The Joint Commission and specialty registries including NCDR, STS and Get With The Guidelines, with MIPS and value pathway submission included. Founded 2023 in Little Rock, Arkansas, with a second office in Seattle. Nathan Myers is president and chief executive; Scott Roper is chief operating officer. The architectural claim is specific and unusual. The company argues that most healthcare artificial intelligence compresses a chart into a summary before the model sees it, because a full inpatient record exceeds standard context windows, and that roughly eighty percent of clinical signal lives in the unstructured prose that summarisation discards. Its stated design processes the entire record including handwriting, and every output cites the passage that supports it. A patent is pending on upstream data structuring. The origin is the fact that shapes this record. AccuCode was founded inside Professional Consulting Services, described as Arkansas's largest third party medical billing firm, and its chief operating officer spent eighteen years there. That relationship matters because the two year accuracy audit the company publicised in August 2026, in which coders certified by the professional coding association measured engine output at above 99 percent accuracy across a large sample, was performed by that same firm, described in the release as a channel partner. It is a related party audit presented as third party verification, and a buyer should treat it as such. The company's own site notably avoids a headline accuracy number, arguing that measurement discipline matters more, and describes validation as hundreds of thousands of records manually confirmed against source documentation and benchmarked against ground truth consensus. Other evidence is genuine. Baptist Health Systems has been a clinical quality abstraction partner since August 2024. A partnership with MedAxiom, the cardiovascular organisation affiliated with the American College of Cardiology, supports the cardiovascular optimisation claim. The trust disclosure is the strongest in this index. The company publishes a publicly linked, daily updated security posture report covering 244 continuously monitored controls, states SOC 2 Type II with scope, commits contractually that customer data is never used to train any foundation model, names its cloud and restricts it to United States regions with no cross border replicas, requires that every person able to access protected health information be based in the United States, and commits to breach notification materially faster than the statutory floor with terms written into every business associate agreement. Scale is the counterweight. The company is unfunded and reported at roughly seven employees, so a buyer is evaluating an exceptional compliance posture attached to a very small operation. Pilots run on one hundred of the buyer's own charts within four weeks, beginning with a signed agreement.

Autonomous medical coding through the XpertCoding product, paired with a business intelligence layer reporting coding accuracy, billing levels and provider performance, with dashboards for fee for service, quality measures and risk adjustment. Founded 2015 in Birmingham, Alabama by two physicians, originally to improve clinical trial access; the first product was XpertTrial, a trials database and patient recruitment platform. Corporate headquarters is now Scottsdale, Arizona with a Birmingham regional office, and company press materials variously give Scottsdale and Phoenix. Led by co founder and chief executive Sameer Ather, a physician with a doctorate, with Mateo Montoya as chief technology officer. The architecture is explicitly hybrid: ensemble machine learning models, neural networks and rules based clinical intelligence together, rather than a single end to end model. Integration is unusually broad at the connection layer, covering API, SMART on FHIR, HL7 ADT messaging and robotic process automation, which suits smaller organizations without modern integration engineering. Published accuracy and turnaround figures do not agree across the company's own materials and should not be quoted without checking the date of the source. Claims located include 95 percent of claims coded within 12 hours at 95 percent accuracy, 98 percent accuracy within 24 hours, and 99 percent accuracy within 24 hours. This is a disclosure quality problem rather than necessarily a performance one, and it is graded as such. Market position is the clearest differentiator in the category. XpertDox targets federally qualified health centers, urgent care, primary care and pediatrics rather than academic medical centers and large integrated delivery networks, and its risk adjustment and quality measure reporting depth fits the value based care arrangements common in that segment. A named FQHC customer is Community Health Programs of the Berkshires, announced November 2025. The company also distributes through billing companies, including a 2024 alliance with Positive Results Billing, and is listed on the athenahealth Marketplace. Funding is small, roughly 2.5 million dollars total, including 1.5 million dollars in 2022 led by the leadership of TN3, an Arizona private equity firm. That capital position, set against enterprise competitors holding tens of millions, is the material risk to record on the supply chain and viability axes.

mPulse reaches health plan members at very large scale and uses models to decide which members to reach. Based in Los Angeles, backed by PSG and previously trading as mPulse Mobile, it describes itself as a health experience and insights company and reports more than four billion consumer touchpoints a year across more than 450 healthcare organisations, including over 50 of the 60 largest health plans and 80 percent of top rated Medicare Advantage plans. It was named a Strong Performer in the Forrester Wave for customer experience platforms in healthcare in the first quarter of 2026, and reported year on year revenue and profitability growth in the same quarter. The platform combines two way conversational artificial intelligence and natural language processing with predictive analytics and omnichannel delivery across text, voice, web, portals and print. A member who texts asking for help finding a doctor receives a provider directory link without a person intervening, and campaigns can hand off to a live agent mid conversation. Real time integration with Epic scheduling supports appointment workflows. Much of the current shape came from acquisition. HealthTrio and Decision Point Healthcare Solutions were bought in December 2023, adding member portals and member experience analytics, and Clarity Software Solutions followed in August 2025, contributing cross channel communication and data from 150 million member communications. Use cases centre on the measures that determine health plan revenue: medication adherence for Star Ratings, preventive screening and quality measure gap closure, member acquisition and retention, and access to care. A published case study describes a Medicare Advantage plan using predictive analytics to identify both the members most likely to rate the plan poorly on the federal experience survey and the members most likely to respond positively to outreach, then targeting calls, mailers and issue resolution accordingly. It reports that members who received outreach disenrolled at 2.7 times a lower rate, that roughly 186 members were retained, worth more than 1.1 million dollars over three years, and a return of 776 percent by the third year.

RxAnte predicts which health plan members will stop taking their medication, and then sells the plan a way to intervene. It is a portfolio company of UPMC Enterprises, the venture arm of the health system, and its president is Aaron McKethan. The analytics come first. Predictive models identify members who are already non adherent and, more usefully, those likely to become so while there is still time to act, scored against the Medicare Star Ratings medication measures, HEDIS measures and patient experience surveys. The company states its analytics cover more than 14 million lives and that it manages Part D star performance for 70 percent of the lives in five star Medicare Advantage prescription drug plans nationally. The targeting criterion is named openly in the product itself. The Value of Future Adherence score, produced by the company's VFA software, identifies members with the greatest cost savings potential, and the company describes it as letting a plan engineer the return on its pharmacy care management programme. Members are ranked by what their non adherence would cost, not by how sick they are. Since 2019 the company has also owned the intervention. Mosaic Pharmacy Service is a working pharmacy for medically complex Medicare members on multiple chronic medications: a virtual visit and enrolment offer, a pharmacist medication review using its Therapeutic Decision Support tool, 30 day supplies delivered in pre sorted pouches including over the counter items, and monthly follow up with prescribers and caregivers. The company has published a matched control analysis of Mosaic within a Medicare Advantage plan, comparing enrollees against members who filled prescriptions elsewhere on total cost of care, unplanned care events and adherence at six months, with a pre stated hypothesis that savings would be greatest in the high scoring subgroup. Named health plan relationships include Aetna and UPMC Health Plan, and its work has appeared in NEJM Catalyst.

Medalogix builds predictive models for home health and hospice and nothing else. Based in Nashville and founded around 2014, led by president and chief executive Elliott Wood, it is described in trade coverage as the only data science company focused entirely on this sector. It absorbed the hospice analytics firm Muse Healthcare in a merger, and Muse now trades as a Medalogix product rather than independently. Three products sit on the same approach. Care predicts hospitalisation risk in home health and recommends a plan built from the histories of similar patients. Pulse, launched in 2022, works visit by visit, drawing on assessment data, vital signs, medications and clinician narrative notes to show how a patient's risk is moving after each contact; the company reports it draws on more than 11 million home health visits and performs over 300 billion calculations. Muse addresses hospice, comparing more than 800 data points for a patient against millions of records to identify when someone is entering their final days. What Muse predicts is death. The company and its customers state precision above 90 percent for identifying a patient within seven days of dying, and the purpose is to send more people rather than fewer: agencies use the prediction to raise visit frequency from nurses and social workers at the end of life, with customers reporting as many as 82 percent more visits than the national average during that period. Reported outcomes elsewhere are operational. The home health product is associated with a near 20 percent reduction in hospitalisation and 2.4 fewer visits per episode, and a separate partner reports an 8.2 percent reduction in unwanted hospital transfers. Distribution runs through the sector's dominant record systems rather than direct. Homecare Homebase, which states it serves around 37 percent of United States home health and hospice providers, is an exclusive partner for the hospice product, and the models also surface inside the MatrixCare workflow. Enterprise customers include Amedisys, Enhabit and AccentCare.

HiLabs cleans healthcare data that other systems then rely on, and its centre of gravity is the provider directory. Founded in 2014 by chief executive Amit Garg and Neel Butala, based in Bethesda, Maryland, it employs around 340 people across four continents and has raised roughly 41 million dollars, including a 39 million dollar Series B in March 2024 led by Denali Growth Partners and Eight Roads Ventures with F-Prime Capital. The platform is MCheck, which ingests, cleans and enriches data for health insurers across provider data accuracy, clinical results, payment accuracy and value based care. The provider directory product validates and enriches more than 60 attributes per clinician, from phone numbers and specialties to whether a practice is accepting new patients, by cross checking signals across thousands of sources on a recurring cadence rather than through periodic one off cleanups. The company states the directory solution is live in most United States states and analyses data covering more than 80 percent of the country's healthcare providers, and it works with CAQH, whose provider data it combines with its own models. The evidence position is unusual for an administrative product. The company's method has been validated in peer reviewed research published in the Journal of the American Medical Association and referenced in a MedPAC report to Congress. The published work found that more than four in five physicians listed in health insurer directories had inconsistent entries, which bears directly on whether the provider directory provisions of the No Surprises Act are being met. The portfolio has since widened. MCheck NetworkIQ was deployed with a national behavioural health organisation serving millions of members. In August 2026 the company announced MCheck Intelligent Outreach, an agentic voice platform that calls providers to confirm and update their directory details, deployed by one of the ten largest United States health plans. Growth leadership includes president and chief growth officer Amir Desai and chief growth officer Robert Renzi.

Machinify is the largest payment integrity organisation in the United States market and it exists as the result of four companies being combined under one private equity owner. Anyone searching for the constituent brands is looking at businesses that now sit inside this one. The sequence matters. In September 2024 New Mountain Capital merged The Rawlings Group, Apixio's Payment Integrity business and VARIS into a single platform. In early 2025 it acquired Machinify Inc, an artificial intelligence software company founded in 2016 in Palo Alto, and named the whole combined entity Machinify, with David Pierre as chief executive. In October 2025 the group acquired Performant Healthcare for a reported 670 million dollars, and through 2026 the Rawlings brand was retired into Machinify. Reported valuation at the time of the Machinify acquisition was around 5 billion dollars on revenue above 500 million. One split is worth recording precisely because it is the kind of detail that causes confusion. Only Apixio's payment integrity business went into this group. Apixio's Connected Care platform and value based care solutions were acquired separately by Datavant, so the Apixio name divided between two acquirers rather than moving as one. What the combined organisation sells to health plans spans subrogation, coordination of benefits, pharmacy payment integrity and complex claim review, delivered as what the company describes as a cloud based data intelligence platform for deploying purpose built artificial intelligence across the payment continuum, supported by clinical expertise and a large claims data asset. Company materials report service to more than 60 health plans, with some sources citing 75 to 85, including many of the twenty largest, alongside expansion into government programmes. An independent assessment worth noting alongside that: analyst trackers continue to place Cotiviti and Optum as the entrenched leaders in enterprise scale payment integrity, describing this company's market leadership as still emerging despite its scale.

Layer Health is a Massachusetts Institute of Technology spin out applying large language models to clinical chart review, founded in 2023 and based in Boston. Its co founders are David Sontag, an MIT professor of machine learning in healthcare who serves as chief executive, with Monica Agrawal, Luke Murray and Divya Gopinath, alongside Steven Horng, an emergency physician and clinical informatician at Harvard Medical School. The first product is called Distill. Rather than summarising a chart for a clinician about to walk into a room, it performs structured abstraction: reading unstructured notes, labs and imaging across a patient's record and extracting the specific fields a downstream process needs, with each extracted field linked back to the evidence in the record that produced it. The stated applications are clinical registry submission, quality measurement, curation of real world evidence, clinical documentation improvement and revenue cycle. The company states the platform works without requiring labelled training data, which is the usual bottleneck in this work. Registry abstraction is the wedge. Hospitals employ nurse abstractors to read charts manually and submit data to national registries in cardiovascular disease, oncology, surgery and other areas, and the work is slow and expensive. Named deployments include White Plains Hospital, Froedtert, and Intermountain Health, which took a strategic investment through Intermountain Ventures and committed to a multi year deployment across 33 hospitals starting with stroke, bariatric surgery and cardiovascular registries. The company also works with the American Cancer Society on abstraction of patient data drawn from across the United States for research. It raised a 4 million dollar seed round in November 2023 from GV, General Catalyst and Inception Health, followed by a 21 million dollar Series A in March 2025 led by Define Ventures with GV and Flare Capital Partners.

ActiumHealth is the healthcare branded patient communication product of Syllable, a Mountain View company that purchased it in March 2024 and now runs it as a division. The name has outlasted both an ownership change and a product change, which is the first thing a buyer should understand about it. It began in 2017 as SymphonyRM under founder Michael Linnert, a patient relationship intelligence product built on the argument that record system data was underused for identifying who needed outreach, and raised roughly 36.5 million dollars across a 10 million dollar Series A in 2019 and a 25 million dollar Series B in May 2021 led by TT Capital Partners with Adams Street. Under Syllable the product described is generative communication automation rather than predictive outreach intelligence, and the company reports more than 70 million calls handled with roughly 70 percent resolved without a person, across inbound and outbound voice, text message, chat and email, in several languages including Spanish and Mandarin. Houston Methodist is named publicly as a reference with a stated staffing capacity gain. Agents identify a caller, find the right provider or department, check availability and confirm appointments, take prescription refill requests into the clinical workflow, and escalate out of scope requests to a human operator with the full conversation context attached so the patient does not repeat themselves. Escalation routing changes by time of day, with urgent clinical questions going to the on call provider after hours while scheduling and refill requests queue for the next business day. A quality monitoring layer launched in October 2025 analyses the calls the agents themselves handle and flags problematic interactions for intervention. Integration with the dominant electronic health record vendor is published as a named product surface. The wider position is worth watching: through 2026 the parent has repositioned as a general purpose agentic voice platform with published gateway services for language models, speech recognition and speech synthesis, a self service sign up and a public showcase spanning home services, mortgage, retail commerce and automotive alongside healthcare. Chief operating officer Carter Dunn. John Voigt was appointed executive vice president for growth and strategy in September 2025.

Authenticx, founded in Indianapolis by former healthcare executive Amy Brown, analyses the conversations healthcare organisations have with patients and members across voice, chat and email, and reports what those conversations reveal at a system level rather than call by call. Its models are described as trained exclusively on healthcare data using a proprietary labelled corpus. The signature one is the Eddy Effect, a friction model that locates the points where people get stuck, confused or lost, and connects those points to consequences a business recognises such as therapy discontinuation, prescription fills and retention. A separate generative model transcribes and summarises conversations for evaluation, and further models cover agent quality, sentiment, unsupervised topic discovery, compliance monitoring and adverse event signal detection. An agent assist product released through the Salesforce marketplace in late 2025 puts historical context, real time guidance and recommended next steps in front of the person on the call, and evaluates interactions against defined rubrics. Customers span pharmaceutical manufacturers, including Eli Lilly for adverse event signal identification, along with insurers and provider contact centres. The company raised 20 million dollars in Series B funding in January 2023 led by Blue Heron Capital.

Attune, based in Chicago and publicly launched in January 2026 under chief executive Matt Coughlin, sells Agentic Voice, an autonomous voice system that holds telephone conversations with patients and health plan members on the organisation's behalf. Rather than following a fixed script, the agent is described as pursuing a goal across multiple steps: identifying a gap in a care plan, placing an outbound call, checking a live schedule, booking an appointment and confirming it, without a person in the loop. It reads and writes through interfaces and webhooks, escalates to staff with the full conversational context attached, retries on failure, and reports sentiment rather than only call metrics. It also navigates phone trees and holds on the line, which extends its use to calls the organisation makes outward as well as inward. The case the company puts forward is a health plan that used the agent to work through its entire Medicare member population completing health risk assessments. Note for readers of this list: despite appearing on a source list of agent assistants, this product does not assist a human agent, it replaces one, which is why it sits with the patient facing voice agents. The company is roughly six months into public operation and much of what this index grades is not yet published.

Laguna Health, founded in 2020 by Yoni Shtein and Yael Adam and based in New York, applies conversational models to the calls that care managers hold with members, principally in the period after a hospital discharge. Its framing is contextual care: a member's record describes their medicine but not their life circumstances, their caregiver's situation or the emotional and practical obstacles that actually determine whether a recovery plan is followed, and those obstacles surface in conversation rather than in data fields. The platform prepares the care manager before a call, surfaces insight during it, drafts the documentation afterward in the style and format each organisation requires, and routes what it heard into care plan changes. A separate product, Laguna Insight, analyses every member interaction on behalf of team leaders and scores whether a care manager noticed and explored the barriers a member hinted at, replacing the practice of supervisors listening to recordings by hand. Buyers are health plans, employers, post acute and home health providers and integrated delivery networks, with quality measure performance an explicit driver. The company has raised over 21 million dollars, including a 15 million dollar Series A in 2023 co led by SemperVirens and HC9 Ventures.

Popai Health, founded in 2024 by chief executive Eyal Gurion with chief product officer Michael Latar, applies healthcare trained voice models to the phone calls that care coordination teams make and take. The company's argument is that roughly two thirds of patient interaction happens by telephone and almost none of it is captured, so the richest source of clinical, operational and social information in a health system evaporates as soon as the call ends. The platform is described in three layers: it ingests conversations from any call channel and handles medical terminology across multiple languages; it makes the aggregate content of every call explorable through dashboards and reports rather than through manual spot check sampling; and it acts, generating compliant documentation into the record, surfacing real time talking points to the person on the call, and triggering escalations to physicians, appointment scheduling, care gap closure and medication adherence follow up. At population level it surfaces risk patterns across thousands of calls. It raised 11 million dollars in November 2025 led by Team8 and New Enterprise Associates with Essen Health Care participating, and states deployment at Essen Healthcare and Clover Health across more than 18 million minutes of patient conversation. Its site publishes a SOC 2 badge and a HIPAA compliance badge.

Oatmeal Health, founded in May 2022 by Jonathan Govette and based in San Jose, sells lung cancer screening programmes to federally qualified health centres and health plans, serving Medicaid and Medicare populations that screening programmes have historically reached least. Its platform, ICARE, runs four stages: a model over structured and unstructured record data that identifies patients meeting the recommended screening criteria, automated scheduling and reminders, a vision transformer that detects and risk stratifies pulmonary nodules on low dose computed tomography, and a language model chatbot that explains results and next steps in the patient's preferred language and books follow up. A clinical team works alongside the software. Integration is deliberately broad, with named record systems and any imaging vendor or archive. Two things a reader should hold together: the company builds its own models rather than deploying somebody else's, which distinguishes it from several peers in this index, and its own site states that the diagnostic component is not yet cleared by the FDA, with clearance expected in early 2027, while press from early 2025 described a reimbursable Medicare covered diagnostic tool.

Lucem Health, founded with Mayo Clinic and based in Davidson, North Carolina under founding chief executive Sean Cassidy, sells early disease detection programmes to health systems under the Reveal name, covering lung cancer, colorectal cancer, liver disease, arrhythmias, type 1 diabetes, progression from prediabetes to diabetes, and lower gastrointestinal disorders. Each programme runs a predictive model over electronic health record data a health system already holds, surfaces patients at elevated risk, and wraps that output in outreach, scheduling and care management so the identified patient actually reaches a test. The company does not build the models. Three of the Reveal programmes were developed with Medial EarlySign, an Israeli company whose algorithmic models are its own product, and the arrhythmia programme runs with iRhythm. Lucem describes its own contribution as operationalising clinical artificial intelligence, a discipline it calls AI SolutionOps, and its founding chief executive has framed the company's problem plainly as integrating tools that already work into workflows that do not accommodate them. It raised a 7.7 million dollar round in May 2023 led by Mayo Clinic, Granger Management and Mercy.

Carna Health is a Boston company founded in 2021 by Dr Salvatore Viscomi that builds screening and care management infrastructure for chronic kidney disease and the wider cardio kidney metabolic cluster. It pairs point of care testing with a platform that ingests results from laboratories, testing devices, record systems and health information exchanges, stages patients, and routes those who need specialist care into a referral pathway. Its distinguishing characteristic is where it operates: national and regional screening programmes in Bermuda, Cameroon, the Philippines, the Dominican Republic and Turkey, with entry into the United States market underway, which is an unusual geographic footprint for any vendor in this index. A strategic agreement with Siemens Healthineers supplies point of care testing systems in emerging markets, and a May 2026 partnership brings the Renalytix kidney risk test onto the platform. The company markets itself as artificial intelligence driven throughout, and the record below records what was actually located behind that description.

Carenostics was founded by Dr Bharat Rao and his son Kanishka Rao after a family member died of chronic kidney disease that had never been diagnosed. The platform reads existing electronic health record data, both structured fields and unstructured notes, to identify patients who already have a chronic disease but carry no diagnosis, and prompts the clinician inside the workflow they are already using. Chronic kidney disease is the lead indication, with asthma, chronic obstructive pulmonary disease and heart failure named as expansion areas, and a separate line of work supporting transplant centre operations. Two design choices define it. Models are tailored to each health system on that system's own local data rather than shipped as one general model, and the company states that no patient information ever leaves the hospital system. Bharat Rao's background is unusually deep for a startup founder in this category: he led artificial intelligence and health analytics at Siemens Healthcare, ran healthcare data and analytics practices at Deloitte and KPMG, and holds the ACM SIGKDD Service Award. The main deployment on the public record is Hackensack Meridian Health, New Jersey's largest health network, which has confirmed the partnership through its own newsroom and shared a Bio-IT World Innovative Practice Award with the company for the kidney disease work.

Arine sells medication intelligence to health plans rather than to hospitals, which makes it the clearest payer side record in this category. The platform ingests clinical, socioeconomic and behavioural data across a plan's membership, identifies members at risk of medication related problems before they produce an event, generates personalised care plans for clinical pharmacists to act on, and separately analyses prescriber behaviour so a plan can direct education and recommendations at the clinicians writing the prescriptions. A third product line targets the Medicare Advantage and Part D quality measures, particularly the triple weighted adherence measures that carry disproportionate weight in the CMS Star Ratings that determine a plan's bonus payments. The company was founded in San Francisco by Yoona Kim, a doctor of pharmacy with a doctorate who serves as chief executive, alongside Penjit Moorhead as chief technology officer and David de Vries as chief operating officer, and it launched under the Arine name in 2019 after operating as Akeso. It has raised roughly 95 million dollars across six rounds through a Series C in June 2025, and holds a HITRUST risk based two year certification obtained in July 2024. Named clients span Medicaid, Medicare Advantage and behavioural health, including the Oklahoma Health Care Authority, Magellan Health, VNS Medicare and MDX Hawaii. Every outcome figure the company publishes is its own, though it names the analytic method behind them, which is more than most.

FeelBetter applies machine learning to polypharmacy, the problem of an older patient accumulating enough medications that the regimen itself becomes the hazard. The platform synthesises longitudinal pharmacy and clinical data across a whole population, identifies the patients at highest risk of near term deterioration or hospitalisation attributable to their medication regimen, recommends specific regimen changes to a clinical pharmacist, and monitors what happens after the intervention. It is organised as four tools: Insight for risk stratification, Navigator for workflow, Action for the pharmacist facing recommendation engine, and Impact for post intervention monitoring. The company was founded in 2018 by Liat Primor, previously VP of global portfolio and chief of staff at Teva Pharmaceuticals, and Yoram Hordan, and operates from Boston and Tel Aviv. It raised 5.9 million dollars in July 2023 bringing total funding to roughly 8 million, which is modest relative to the health systems it serves. Named customers span three distinct buyers: Atlantic Health System in New Jersey across its accountable care organisations, Americare in long term care, and Leumit Health Services, an Israeli health maintenance organisation. The evidence position is unusual for a company this size, since investigators at Brigham and Women's Hospital published a retrospective cohort of 108,817 patients in the American Journal of Managed Care evaluating the platform's recommendations. The company markets its approach under a coined term, Pharmaco-Clinical Intelligence, which describes a market position rather than a method, and almost no technical, security or compliance detail is published alongside it.

Credo Health, based in Denver and led by founder and chief executive Carm Huntress, addresses the problem underneath every other product in this category: you cannot summarise a record you do not have. Its PreDx product delivers a concise clinical history, pre encounter risk analysis and HEDIS gap closure before a visit, and the retrieval machinery beneath it is what distinguishes the company. Care Map, launched in October 2025, maps a patient's complete encounter footprint. It reviews the records already held, identifies every location where care was likely delivered across hospitals, clinics and specialists both in and out of network, and crucially spots signals that another record should exist at all, the worked example being a cardiology referral with no corresponding cardiology note. It then checks each likely site against Carequality, CommonWell, eHealth Exchange and regional health information exchanges to establish what is available and what is still missing. What happens next is the part nobody else does. The company states that 30 to 50 percent of high value encounters are not returned digitally by those networks, and it pursues them anyway: AI agent assisted workflows contact source providers by telephone, through secure portals and by fax to recover what the exchanges did not deliver. Everything is then cleaned, deduplicated and stitched into a single source cited history. Buyers are value based care providers, management services organisations and health plans, with Medicare populations called out as the setting where care is most distributed and retrieval hardest. The company raised 5.25 million dollars in seed funding led by FCA Venture Partners with Hannah Grey VC, FirstMile Ventures and SpringTime Ventures, and has announced partnerships with Vim for point of care EHR delivery and with HealthMark Group on release of information. Name collision worth noting: credo.health carries content for an unrelated Digital Health Passport product. This record concerns credohealth.com.

Kennar Health, operating as Toothpicker Holdings and based in Hicksville, New York, sells what it calls an AI workforce for value based care networks. A scribe listens to the patient interaction and structures clinical data in real time, and an analysis layer surfaces HEDIS quality gaps and HCC risk opportunities from patient data so a provider can act inside the existing workflow rather than switching systems. It also automates transitions of care. Reported figures are 70 percent capture rates, a 0.2 risk adjustment factor lift and two hours per day saved, none of them substantiated. It describes EHR agnostic integration and a multi tenant architecture serving health systems, independent practice associations, accountable care organisations and management services organisations. It is filed under value based care intelligence rather than clinical summarisation, and cross listed into ambient scribes, because of what it delivers. The record is unified and insights are surfaced, but the measured outputs are captured codes, closed quality gaps and risk score movement rather than a summary a clinician reads. The reason this record is worth having despite thin evidence is a compliance argument nobody else in this index makes. Asked how its data holds up under RADV audit, the company answers that it captures HCC codes PROSPECTIVELY at face to face encounters with MEAT compliant documentation support, states that retrospective chart review is the primary driver of RADV clawback risk, and argues its point of care model removes that exposure by design. It further states that all data traces back to a face to face encounter with an approved provider type, meeting CMS encounter level evidentiary standards, and that output is standardised audit ready supplemental data rather than non standard manual submission. That distinction between prospective capture and retrospective review is the sharpest framing of audit risk found anywhere in this index, and it is discussed on the governance axis alongside the fact that the same company markets a specific risk score lift.

Clinical AI built for health plans rather than providers, which is what distinguishes it in this category. Where most indexed RCM vendors help providers get paid, Anterior automates the clinical review work inside payer organisations: prior authorization, risk adjustment, care management and payment integrity. Founded 2022 by Abdel Mahmoud, a physician, and Zahid Mahmood, with the premise drawn from observing that thousands of nurses and clinicians inside payer organisations are pulled away from patient care to perform administrative tasks that nonetheless require clinical judgement. The technical claim is a proprietary clinical reasoning architecture rather than general-purpose generative AI applied to medical text, which matters because the task is evaluating whether a specific patient's documented clinical picture meets a specific payer's medical necessity criteria, not summarising a chart. The company reports serving payer organisations covering over 50 million lives, 99.24 percent clinical accuracy, and a 76 percent increase in auto-approvals for customers. Funding totals roughly $63 to $64 million across three rounds, including a $20 million Series A led by NEA in 2024 and a $40 million round in February 2026, with investors including Sequoia Capital, NEA, FPV and Kinnevik. Context that makes this category consequential right now: sweeping federal prior authorization and interoperability requirements took effect from January 2026, mandating electronic submission and faster turnaround, which is driving payer investment in exactly this automation. That timing cuts both ways, and the index should say so. The same underlying capability that speeds legitimate approvals is the capability behind automated denials, and industry commentary in 2026 documents payers deploying machine learning to issue rapid denials on high-cost services. Anterior's reported metric is increased auto-approvals specifically, which is the favourable direction, but buyers and readers should understand that a clinical reasoning engine inside a payer is a utilization control system regardless of which direction it is tuned.

Digital cognitive screening built for population scale deployment inside health system workflows rather than for depth of assessment, which is the strategic difference from others in this category. The core product is a three minute patient-guided test producing instant objective scoring with DSM-5 aligned output, deliberately sized to fit inside a Medicare Annual Wellness Visit without adding clinician burden or requiring specialised training to administer. The company positions cognitive function as something to be checked routinely like a vital sign, targeting the detection gap it cites where roughly 80 percent of adults aged 65 to 80 receive no routine cognitive screening. Founded 2012 by Elli Kaplan with academic co-founders including Elizabeth Buffalo and cognitive impairment researcher Stuart Zola, with leadership backgrounds at UCSD, the Atlanta VA Medical Center and Emory. Reports 25 peer reviewed papers, 11 patents, FDA Class II registration, more than $62.8 million in venture funding plus $4.3 million in grants from the National Institute on Aging, the Alzheimer's Drug Discovery Foundation and the Georgia Research Alliance, and over 200,000 assessments delivered. Named health system customers include Sutter Health, Providence and Stanford Medicine, with reported reach across more than 15,000 clinicians. An important historical correction the company makes itself and which older coverage gets wrong: Neurotrack originated in eye-tracking based cognitive assessment, and much third party writing still describes it that way, but the company states plainly that while digital eye tracking was among its first technologies it is not part of its current clinician product suite, which now uses patient-led tests selected for validity, accessibility and ease of administration. Tests use culturally agnostic symbols and numbers by design. Also supports RADV audit documentation and Medicare Advantage quality workflows.

Autonomous medical coding platform spun out of Mass General Brigham in 2019, built on coding AI the founding team originally developed inside that health system in 2016. Uses machine learning, deep learning, and natural language processing to translate clinical documentation in the EHR directly into ICD-10, CPT, and related billing codes across radiology, pathology, surgery, gastroenterology, and inpatient professional coding, with a continuous feedback loop from real-time audit. Reported in use at more than 25 provider organizations representing over 200 hospitals and 50,000 providers, and ranked number one by KLAS Research in the Reduce Cost of Care category. Notable in this index as one of the few vendors selling genuine autonomy in a high volume administrative workflow rather than assistive support.

Risk adjustment platform built on what the company calls neuro symbolic AI, combining machine learning with an explicit clinical knowledge graph to link every suggested hierarchical condition category code to specific MEAT based clinical evidence. Positions this explainability as audit defense under tightening CMS RADV enforcement, covering prospective, retrospective, and audit workflows for health plans, health systems, and at risk provider organizations.

Retrospective risk adjustment and quality platform whose Evidence Validation Engine automates medical record retrieval, parses charts, and populates abstraction fields for coder review, supporting HEDIS quality abstraction and RADV audit submissions alongside risk adjustment coding. Founded in 2009 as a medical record retrieval business and since rebuilt around AI and natural language processing, serving health plans and risk bearing providers across Medicare Advantage, ACA Marketplace, and Medicaid.

Clinician copilot that ingests data across the EHR, health information exchanges, insurance claims, and care gap files, then uses proprietary language models to classify documents and extract structure from free text, producing a consolidated Patient Portrait at the point of care. Surfaces suspected chronic conditions never explicitly documented, infers hierarchical condition categories for risk adjustment, and supports care gap closure, with every insight linked back to the underlying clinical evidence. Sold primarily into value based primary care.

Medication access and financial navigation platform that identifies financially at risk patients, matches them against a large network of financial assistance and manufacturer programs, and automates enrollment inside health system workflows using live EHR data. Combines a care team facing platform, a patient facing self serve experience, and a tech enabled service arm pairing automation with human navigators. Serves health systems, oncology practices, infusion centers, pharmacies, and life sciences companies.

AI enabled value based care enablement platform for health systems and clinically integrated networks, combining a proprietary predictive model with virtually embedded Healthguides, medical assistants trained in data science who work under licensed clinical supervision to extend care team reach. The platform identifies high risk patients, coordinates referrals and prior authorization, and supports performance in risk based contracts. Formed in 2023 and built partly on the acquired value based care services division of an analytics vendor.

Health benefits navigation and care platform for self insured employers and health plans, indexed for its AI navigation layer with the surrounding care services as context. WayFinding is a generative AI experience launched in 2024 and scaled through 2025, combining benefits navigation, clinical guidance, and care access in one interface, delivering tailored recommendations from a member's own history so a member can determine what is covered, what it will cost, and where to go. Agentic capabilities were added in January 2026. The company completed a $621 million merger with Accolade in April 2025, taking the formerly NASDAQ listed company private and combining WayFinding and the Cancer Care, Surgery Care, Weight Health, and pharmacy benefit experiences with Accolade's health advocacy, expert medical opinion, virtual primary care, and its True Health Actions platform, which draws on employer data, health plan data, and electronic health records for targeted guidance. The combined organization reports serving more than 20 million members across more than 1,700 employer and health plan clients. Buyers should be clear that this is a hybrid: a substantial share of what is delivered is human advocacy, virtual clinical care, and second opinion services rather than AI. A $126 million Series D in May 2024 was raised specifically to build AI capability. Led by Glen Tullman.

AI utilization management, and the only vendor in this index positioned to sit between payer and provider rather than serving one side. The Dragonfly platform (formerly CORTEX) uses real time predictive analytics to continuously assign an objective medical necessity score, the proprietary Care Level Score, and an anticipated level of care for every patient, with the stated intent of removing subjectivity from patient status determination so both parties work from the same evidence. Product lines cover Utilize for utilization review and case management, Navigate for discharge readiness and length of stay, Advise for physician advisor workflow and peer to peer escalation, and revenue integrity for denials and appeals. Precision UM is the deepest tier, a shared utilization management approach between a health system and a health plan built on common clinical data and historical determination patterns. Integration with the EMR is bidirectional. The company also sells Physician Advisor Services, supplementing night and weekend coverage or operating fully outsourced, so buyers should separate the platform from the staffed service. Named outcome: AnMed reported 14.6x return on investment over a twelve month period and 1,221 hours of front end review time saved through Precision UM with a national health plan. A third party study found Dragonfly rendered clinical review determinations 38 percent faster than fax and 15 percent faster than through the EMR. Headquartered in Franklin, Tennessee; co-founded by Joan Butters.

Healthcare data and agentic artificial intelligence platform, described by the company as an agentic cloud for healthcare, built in three stages: data connectivity integrating major electronic health record systems with payer claims, pharmacy, laboratory, remote monitoring and social determinants sources; applications on top of that data; and autonomous agents on top of those. Gravity is the underlying data and intelligence platform, described as continuously trained on real world healthcare data including claims denials and edge cases, which the company argues gives each new agent institutional context at launch. Sara is the assistant line spanning insights, care management and clinical documentation through Sara Scribe. Named agent products now include Provider Copilot with pre visit summary and ambient scribing, an agentic access centre, and Flow Auth for prior authorisation automation. The product estate has widened considerably through five acquisitions. Humbi AI added actuarial intelligence, Cured added a healthcare native customer relationship platform, Pharmacy Quality Solutions added pharmacy quality, Story Health arrived in September 2025 bringing continuous specialty care delivered by live health coaches working alongside agents with remote biometric monitoring, and CaduceusHealth was acquired in May 2026, a revenue cycle management services provider whose United States based team serves nearly 4,000 providers and manages five billion dollars in gross patient charges annually. That last acquisition extended the Flow suite into full stack revenue cycle operations for ambulatory care. On the payer side, Galaxy is the risk adjustment and analytics platform, joined by a Galaxy utilisation management product for health plans. Independent validation is the strongest in this index and is current. In the 2026 Best in KLAS awards the company took the top score in three categories: Gravity at 93.2 for data analytics platform for providers against a market average of 83.9, Galaxy at 90.5 for data analytics platform for payers against an average of 87.2, and Cured at 90.1 for customer relationship management platforms, its third consecutive win in that category. Scores derive from validated interviews with customers rather than vendor submissions. Infrastructure partnerships are named rather than implied, spanning a multi year strategic collaboration with Amazon Web Services, validated partner status with Databricks, and a partnership with Snowflake. A joint centre of excellence with a services firm and an alliance in the United Arab Emirates announced in April 2026 extend delivery capacity and international reach. Customers include Kaiser Permanente, Ascension and Trinity Health, with six of the top 10 United States health systems reported, alongside Carina Health Network covering more than 1.5 million Coloradans, a five year engagement with Community Care of North Carolina, and a virtual heart failure programme with Allina Health Minneapolis Heart Institute. Founded 2014, headquartered in San Francisco, 675 million dollars raised including a 275 million dollar Series F, with Kaiser Permanente and Banner Health among investors while also being customers. Two things a reader should weigh. The Centers for Medicare and Medicaid Services accepted the company's application under Story Health Partners for the Advancing Chronic Care with Effective, Scalable Solutions model, positioning it to participate at the programme's July 2026 launch across both cardio kidney metabolic tracks. Taken together with a revenue cycle services acquisition and a coaching based care model, the company is moving from selling software to health systems toward operating care and delivering services with people. That is the shape this index screens out when it constitutes the whole business, and it does not here, because the platform remains licensable on its own terms. It is a direction worth watching rather than a finding. And no pricing of any kind was located.

Housing stability platform sold to health plans and employers, addressing housing instability as a driver of avoidable medical utilization. The model is explicitly hybrid and the company describes it as human led and AI accelerated: licensed social workers and housing specialists called Care Guides deliver the intervention, supported by proprietary AI for acuity stratification, case summarization, and predictive housing matching against a curated database of public and non public affordable housing inventory. The company states it deliberately avoids general purpose language models in favor of a purpose built social determinants matching framework. Serves Medicaid, Medicare Advantage, D-SNP, commercial, and employer sponsored populations across the full continuum from crisis intervention to long term tenancy support, and reports partnerships with more than 17 national, regional, and state health plans across 10 states including four of the largest US payers, with a named Medicaid housing supports contract from UnitedHealthcare of New Jersey. Reported results include more than half of enrolled members stabilized within 90 days. Founded 2020; raised a $20 million Series A in June 2026 led by Aquiline with Flare Capital Partners.

Value based care enablement platform for Medicare providers: AI powered predictive insights identify the highest urgency patients so care teams intervene before costs escalate, alongside financial risk modeling and workflow automation for scheduling and post discharge follow up. Supports more than 10,000 providers across 40+ states serving roughly 250,000 Medicare beneficiaries, with about $3.6 billion in annualized medical spend under management. Raised $110 million in July 2026 ($50 million equity led by Andreessen Horowitz plus a $60 million credit facility). Pearl is a hybrid: predictive software wrapped in risk bearing value based care enablement, and this record covers the platform.